Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Srishti Gupta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
- Beta
- 1.71
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 5.09
Financials
Revenue
$0.00-100.0%Net Income
$-18.87MEBITDA
$-18.11MFree Cash Flow
$-16.90MEPS (diluted)
$-0.16Shares Outstanding (diluted)
115.72M+98.9%Operating Expenses
$20.30MCash & Debt
$190.85MReturn of Capital
$0.00Revenue by Segment (annual)
$27.64MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-46.27M | $-0.46 |
| 2024 | $0.00 | $-162.26M | $-4.46 |
| 2023 | $4.49M | $-1.47B | $-17.62 |
| 2022 | $-10.70M | $-967.52M | $-30.38 |
| 2021 | $88.03M | $-2.33B | $-30.70 |
| 2020 | $1.54B | $470.92M | $8.07 |
| 2019 | $30.00M | $-1.45B | $-25.53 |
| 2018 | $53.78M | $-402.83M | $-6.92 |
| 2017 | $11.27M | $-298.24M | $-5.13 |
Valuation
NBPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·20d ago·Positive
NovaBridge Biosciences (NBP) Discusses Mature Givastomig Data and Registrational Development Strategy Transcript NovaBridge Biosciences (NBP) Discusses Mature Givastomig Data and Registrational Development Strategy Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience Biotechnology Executive Brings Extensive Capital Markets, Financing, Corporate Strategy and Investor Relations Experience
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesoph
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)
View source ↗ - Newsglobenewswire.com·40d ago·Negative
…t. 13, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. (“Visara” or the “Company”), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (“NovaBridge”) (NASDAQ: NBP), today announced that it has entered into an exclusive license agreement (the “License Agreement”) with Wuhan Hiteck Biological Pharma Co., Ltd.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
…vaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director ROCKVILLE, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced the appointment of Martin Dewhurst to its Board of Directors (the “Board”) as an independent director, and as a memb…
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
NovaBridge Biosciences to Participate in September Investor Conferences ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company's leadership will participate in the following investor conferences in September 2026: Conference details: Cant…
View source ↗ - Newsseekingalpha.com·94d ago·Positive
NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·94d ago·Positive
…alf 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution ROCKVILLE, Md., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today reported financial results for the six months ended June 30, 2026, and provided a business update. During the first half of 20…
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
… 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026 ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent…
View source ↗
Earnings
Wed, Mar 31(in 4 months)
Consensus estimate $-0.19 per share
Typical surprise +58.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 20$-0.02 vs $-0.03beat
- Thu, Jul 30$-0.22 vs $-0.01miss
- Thu, Dec 18$-0.03 vs $-0.06beat
- Tue, Aug 26$-0.03 vs $-0.06beat
- Thu, May 15$-0.02 vs $-0.06beat
- Mon, Mar 31$-0.06 vs $-0.06beat
Estimates and results for NBP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NBP officers and directors.
- Bought
- $663k
- Sold
- $154k
3 trades
7 trades
- Hagler Mark Arnoldbought
- Hagler Mark Arnoldbought
- Dennis Phillip Andrewsold
- Cao Sean Wuxiongsold
- Xu Cong Clairesold
- Xu Cong Clairesold
- Dennis Phillip Andrewsold
- Xu Cong Clairesold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NBP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
